Business Wire

NTT-ELECTRONICS

16.9.2022 08:01:41 CEST | Business Wire | Press release

Share
NTT Electronics expands its 400G Coherent DSP line-up into Data Center Interconnects and longer reach networks

NTT Electronics Corporation, a leading supplier of coherent Digital Signal Processor (DSP) solutions to system and module manufacturers worldwide, today announced addition of a low power consumption 400G Coherent DSP to its product portfolio for enabling multi-rate Ethernet transport and applications far beyond Data Center Interconnects. The new DSP ExaSPEED400-R focuses on 400ZR and OpenZR+ interoperable QSFP-DD applications, and achieves 20% less power consumption than its upper-compatible ExaSPEED400 for CFP2-DCO applications.

The new ExaSPEED400-R supports both OIF 400ZR and OpenZR+ MSA 100G-400G specification at the line side, and provides Ethernet transport with 8x25G-NRZ and 8x50G-PAM4 interfaces at the client side. It supports fully flexible Ethernet formats: 1x100GE, 2x100GE/1x200GE, 3x100GE, and 4x100GE/2x200GE/1x400GE.

“This is a very exciting development enabling the use of a low-power DSP in interoperable coherent QSFP-DD modules for an expansion of the application space by cloud network operations and service providers,” said Atul Srivastava, Co-chair of the OpenZR+ MSA Group.

At ECOC 2022, NTT Electronics will show a video demonstration of QSFP-DD module interoperability at 400G OpenZR+ including over 1000km straight fiber transmission, with the support of its QSFP-DD partners Fujitsu Optical Components Ltd., Molex LLC, and NEC Corporation.

Mogi Masahiro, President, Fujitsu Optical Components America Inc, commented as below. “For many years, from the inception of the coherent optical transmission technology, NTT Electronics and Fujitsu Optical Components (FOC) have established a successful partnership to bring the most advanced optical transceiver products to market. We are now very pleased that interoperable coherent transmission has been achieved successfully between FOC’s QSFP-DD optical transceiver, incorporating NTT Electronics’ new ExaSPEED400-R DSP chip, and multi-vendors’ QSFP-DD transceivers. Using FOC’s optical transceiver which enables transmission distance extension with low-power consumption, we are very pleased to be contributing to the ecosystem of interoperable coherent transceivers for data center and service provider networks.”

“Molex is focused on expanding the reach for data center interconnect beyond 120km, recognizing the industry need for significantly improved performance,” said Joseph Chon, director, Coherent Technology and Product Line Management, Molex Optoelectronics. “Collaborating with NTT Electronics and its module partners has accelerated the overall business opportunity for the interoperable QSFP-DD Interconnect Systems and we look forward to supporting evolving customer requirements in this space.”

“We have been developing and producing the state-of-art digital coherent transceivers for more than a decade.” said Akio Goto, General Manager of Photonic Device Development Department, NEC, “And now, as part of continuous collaborations to expand the digital coherent business with NTT Electronics, we have succeeded in developing QSFP-DD, competitive in the market, by using our technical assets and experience. We are accelerating their deployments for various markets.”

ExaSPEED400-R is now ramping up its production volume.

About NTT Electronics

NTT Electronics has been developing and commercializing optical communications devices since 1995. It has complete portfolio of optical and electronics products to cover the industry needs for 100G-and-beyond systems, ROADM components and FTTH networks. Since 2012 NTT Electronics has been delivering its flag-ship 100G coherent DSP that has been widely adopted in the industry. NTT Electronics is headquartered in Yokohama, Japan with offices in Milan, Italy, San Jose, CA, and Shenzhen, China. For more information, go to http://www.ntt-electronics.com/en/about/overview.html

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005082/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye